| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
82,788,000 |
| Market
Cap: |
422.22(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.52 - $7.07 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Solid Biosciences is engaged in curing Duchenne muscular dystrophy (Duchenne), a genetic muscle-wasting disease predominantly affecting boys. SGT-001 and SGT-003 are Co.'s gene transfer candidates. SGT-001 and SGT-003 are designed to address the underlying genetic cause of Duchenne by delivering a synthetic transgene that produces dystrophin-like protein that is only expressed in muscles of the body, including cardiac and respiratory muscles. Co.'s SGT-001 and SGT-003 vectors are derived from a naturally occurring, non-pathogenic virus called adeno-associated virus, which were selected for their ability to enter skeletal, diaphragm and cardiac muscle tissues.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
6,254,405 |
10,570,378 |
| Total Buy Value |
$0 |
$0 |
$26,099,164 |
$49,968,854 |
| Total People Bought |
0 |
0 |
4 |
5 |
| Total Buy Transactions |
0 |
0 |
4 |
7 |
| Total Shares Sold |
6,173 |
6,173 |
65,843 |
104,305 |
| Total Sell Value |
$30,759 |
$30,759 |
$305,675 |
$451,632 |
| Total People Sold |
2 |
2 |
7 |
8 |
| Total Sell Transactions |
2 |
2 |
16 |
26 |
| End Date |
2025-09-04 |
2025-06-03 |
2024-12-03 |
2023-12-04 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ganot Ilan |
|
– • – |
2025-11-10 |
4 |
S |
$4.12 |
$13,505 |
D/D |
(3,278) |
95,412 |
|
-31% |
|
| Brooks Gabriel |
Chief Medical Officer |
• – – |
2025-10-20 |
4 |
S |
$5.96 |
$17,254 |
D/D |
(2,895) |
33,819 |
|
12% |
|
| Brooks Gabriel |
Chief Medical Officer |
• – – |
2025-10-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,750 |
36,714 |
|
- |
|
| Smith Ian F |
|
– • – |
2025-10-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,573 |
126,692 |
|
- |
|
| Smith Ian F |
|
– • – |
2025-07-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,573 |
122,119 |
|
- |
|
| Smith Ian F |
|
– • – |
2025-04-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,574 |
117,546 |
|
- |
|
| Kahn Clare |
|
– • – |
2025-03-11 |
4 |
B |
$5.34 |
$9,924 |
D/D |
1,860 |
2,960 |
0.01 |
14% |
|
| Bcls Ii Equity Opportunities Gp, Llc |
|
– – • |
2025-02-19 |
4 |
B |
$4.03 |
$4,030,000 |
I/I |
1,000,000 |
5,034,582 |
0.01 |
-25% |
|
| Edelman Joseph |
Director |
– • • |
2025-02-19 |
4 |
B |
$4.03 |
$20,150,000 |
I/I |
5,000,000 |
11,833,539 |
2.25 |
-25% |
|
| Gross Phillip |
10% Owner |
– – • |
2025-02-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,995,539 |
|
-11% |
|
| Gross Phillip |
10% Owner |
– – • |
2025-02-18 |
4 |
B |
$7.56 |
$1,909,240 |
I/I |
252,545 |
4,248,084 |
1.5 |
-11% |
|
| Hanrahan Jessie |
Chief Regulatory Officer |
• – – |
2025-02-14 |
4 |
S |
$3.96 |
$12,193 |
D/D |
(3,079) |
19,281 |
|
-19% |
|
| Herzich Paul |
Chief Technology Officer |
• – – |
2025-02-14 |
4 |
S |
$3.96 |
$10,644 |
D/D |
(2,688) |
18,388 |
|
-19% |
|
| Cumbo Alexander |
President and CEO |
• • – |
2025-02-14 |
4 |
S |
$3.96 |
$45,005 |
D/D |
(11,365) |
60,717 |
|
-19% |
|
| Ganot Ilan |
|
– • – |
2025-02-14 |
4 |
S |
$3.96 |
$6,776 |
I/I |
(1,711) |
14,839 |
|
-19% |
|
| Brooks Gabriel |
Chief Medical Officer |
• – – |
2025-02-14 |
4 |
S |
$3.96 |
$12,894 |
D/D |
(3,256) |
22,812 |
|
-19% |
|
| Tan Kevin |
CFO & Treasurer |
• – – |
2025-02-14 |
4 |
S |
$3.96 |
$12,529 |
D/D |
(3,164) |
32,250 |
|
-19% |
|
| Howton David T |
Chief Operating Officer |
• – – |
2025-02-14 |
4 |
S |
$3.96 |
$22,022 |
D/D |
(5,561) |
24,789 |
|
-19% |
|
| Hanrahan Jessie |
Chief Regulatory Officer |
• – – |
2025-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,125 |
22,360 |
|
- |
|
| Herzich Paul |
Chief Technology Officer |
• – – |
2025-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,187 |
21,076 |
|
- |
|
| Cumbo Alexander |
President and CEO |
• • – |
2025-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
30,031 |
72,082 |
|
- |
|
| Ganot Ilan |
|
– • – |
2025-02-13 |
4 |
OE |
$0.00 |
$0 |
I/I |
4,861 |
16,550 |
|
- |
|
| Brooks Gabriel |
Chief Medical Officer |
• – – |
2025-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,937 |
26,068 |
|
- |
|
| Tan Kevin |
CFO & Treasurer |
• – – |
2025-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,625 |
35,414 |
|
- |
|
| Howton David T |
Chief Operating Officer |
• – – |
2025-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,687 |
30,350 |
|
- |
|
177 Records found
|
|
Page 1 of 8 |
|
|
0.11 (2.11%) 
